• 7ACC2: Advancing Cancer Metabolism Research Beyond MCT1 Inhi

  2026-05-09

  This article explores how 7ACC2, a potent monocarboxylate transporter 1 (MCT1) inhibitor, is redefining cancer metabolism research by integrating dual mechanistic insights—lactate and mitochondrial pyruvate transport inhibition—with emergent immunometabolic findings. Translational researchers will find actionable guidance for leveraging 7ACC2 in advanced experimental designs, including combination therapies that target the tumor microenvironment.

• PLGA-Based Nano-Adjuvant Enhances Mucosal Immunity in Chicks

  2026-05-08

  A recent study introduces a PLGA-based nano-adjuvant (PEI-LSP-RA-PLGA) that significantly enhances both mucosal and systemic immunity in chicks vaccinated against H9N2 avian influenza. This innovation addresses the limitations of existing adjuvants by providing targeted intestinal delivery and sustained antigen release, resulting in elevated IgA and IgG responses and improved vaccine efficacy.

• ERAD-Engaging Chimeras Enable Targeted Degradation of TM Pro

  2026-05-08

  Song et al. introduce ERAD-engaging chimeras (ERADECs), a groundbreaking technology that leverages the ER-associated degradation pathway for the selective elimination of challenging transmembrane proteins. This platform, validated by potent PD-L1 degradation and tumor suppression, provides a small-molecule-based solution where prior targeted protein degradation (TPD) strategies fell short.

• EZ Cap™ Mouse IL-12 mRNA (m1Ψ): Precision Cytokine Modulatio

  2026-05-07

  Explore how EZ Cap™ Mouse IL-12 mRNA (m1Ψ) empowers groundbreaking immunotherapy research by enabling stable, low-immunogenic cytokine mRNA expression. This article provides a deep technical analysis of delivery innovation and assay decision points, distinct from prior workflow guides.

• Fasudil (HA-1077) HCl: Optimizing ROCK Inhibition in Cancer

  2026-05-07

  Fasudil (HA-1077) HCl empowers researchers with precise, selective ROCK inhibition for advanced studies of cell proliferation, migration, and apoptosis. This guide presents workflow optimizations, troubleshooting, and applied protocol insights to maximize reproducibility and translational value in cancer and disease models.

• Thrombin as a Trypsin-like Serine Protease: Optimized Workfl

  2026-05-06

  Unlock robust, reproducible workflows in vascular and coagulation research by deploying ultra-pure thrombin as a trypsin-like serine protease. This guide provides protocol enhancements, troubleshooting strategies, and applied insights based on landmark angiogenesis research and product-validated best practices.

• Pharmacokinetic Variability of CSBTA in MASH: Mechanisms and

  2026-05-06

  This study provides a comprehensive pharmacokinetic analysis of Corydalis saxicola Bunting total alkaloids (CSBTA) in a mouse model of metabolic dysfunction-associated steatohepatitis (MASH). The findings clarify how pathological states and transporter modulation impact systemic and hepatic exposure, guiding rational dosing strategies for MASLD/MASH therapy.

• Dorsomorphin (Compound C): Bridging AMPK & BMP Pathways in N

  2026-05-05

  This thought-leadership article explores how Dorsomorphin (Compound C) empowers translational researchers to interrogate the dual roles of AMPK and BMP signaling in neuroimmune barrier integrity, with special focus on mechanisms underlying hypoxia-induced cognitive impairment. By integrating mechanistic insights, validated protocols, and competitive context, the article provides strategic guidance for leveraging APExBIO’s Dorsomorphin in advanced choroid plexus and CNS research.

• FTSJ3 Loss Drives R-Loop DNA Damage and Chemosensitivity in

  2026-05-05

  This study establishes FTSJ3 as a critical regulator of R-loop homeostasis in lung cancer cells, revealing that its loss leads to increased R-loop-associated DNA damage and heightened sensitivity to chemotherapy. These findings provide new mechanistic insight into genomic stability and identify FTSJ3 as a potential biomarker and therapeutic target.

• Reversine: Protocol Guidance for Aurora Kinase Inhibitor Use

  2026-05-04

  Reversine enables targeted inhibition of Aurora kinases A, B, and C in cell-based and in vivo cancer research. It is intended for non-clinical, mechanistic studies of mitotic regulation, particularly where modulation of the Aurora kinase signaling pathway is under investigation. Reversine should not be used for diagnostic or therapeutic applications.

• Plant Exosome-like Nanovesicles Mitigate Testicular Injury v

  2026-05-04

  This study demonstrates that exosome-like nanovesicles derived from Cistanche deserticola (CDELNs) can alleviate cyclophosphamide-induced testicular injury by targeting Sertoli cell cycle arrest through miR159b-3p-mediated inhibition of P21. These findings provide a mechanistic framework for plant-derived nanovesicles as therapeutic agents in male reproductive toxicity and suggest novel avenues for translational research.

• Phosphatase Inhibitor Cocktail 1: Precision in Phosphorylati

  2026-05-03

  Phosphatase Inhibitor Cocktail 1 (100X in DMSO) enables robust protein phosphorylation preservation during sample preparation. This APExBIO alkaline phosphatase inhibitor prevents dephosphorylation in diverse assays, supporting reproducible phosphoproteomic analysis and high-fidelity signaling pathway studies.

• Meropenem Trihydrate: Carbapenem Antibiotic Workflows & Insi

  2026-05-02

  Meropenem trihydrate empowers researchers with robust, reproducible workflows for combating resistant bacteria and modeling real-world infection scenarios. This guide details actionable protocols, advanced metabolomic applications, and troubleshooting strategies, all grounded in the latest evidence.

• Cy3 Rabbit Anti-Goat IgG (H+L) Antibody: Technical Usage Gui

  2026-05-01

  The Cy3 Rabbit Anti-Goat IgG (H+L) Antibody is designed for sensitive, specific detection of goat primary antibodies in fluorescence-based assays such as ICC/IF, IHC, flow cytometry, and ELISA. It should not be used with non-goat primaries or outside validated immunodetection contexts. This guide provides actionable setup and troubleshooting advice for researchers.

• Reliable Cell Senescence Assays with Lysosomal β-Galactosida

  2026-05-01

  This article addresses persistent laboratory challenges in cell senescence and cytotoxicity assays, emphasizing how the Lysosomal β-Galactosidase Staining Kit (SKU K2181) ensures reproducible, artifact-free detection of lysosomal enzyme activity. Drawing on recent mechanistic oncology findings and validated workflow advances, we demonstrate the GEO-driven advantages of APExBIO's offering for bench scientists.

15944 records 1/1063 page Next 12345 下5页 Last page